Replies to post #245429 on Biotech Values

[Biowatch]

Botox_&_other_cosmetic_injections may be recession resilient

https://www.marketwatch.com/story/a-botox-index-why-sales-of-cosmetic-injections-arent-disappearing-amid-economic-uncertainty-3e5ab651

"There might be some short-term pressures on perhaps new patients entering the category," said Carrie Strom, president of Global Allergan Aesthetics at AbbVie, "but the patient base is highly composed of continuing or existing patients. They see it differently. They see it like, 'This is a part of my routine.'"

There were about 3.6 million instances of someone getting a botulinum toxin injection for cosmetic purposes in 2021, a 40% jump over 2020, according to the American Society for Aesthetic Plastic Surgery. Customers, who are primarily women, pay $450 on average for each shot in cash.

Even with the threat of a recession, ongoing layoffs in the tech and media sectors, and months of record inflation, there is little expectation that bottles of Botox, Xeomin, or Dysport are about to gather dust. These products have a kind of staying power that's more akin to a spending-habit staple than a discretionary purchase for many of their users.

[DewDiligence]

1Q23 worldwide Botox sales=$1.378, +1% QoQ*, +10%YoY:

https://news.abbvie.com/news/press-releases/abbvie-reports-first-quarter-2023-financial-results.htm

• US therapeutic: $587M (-4% QoQ, +18% YoY)
• US cosmetic: $409M (-3% QoQ*, -1% YoY)
--
US total: $996M (59% therapeutic; 41% cosmetic) was 72% of worldwide total


• Ex-US therapeutic: $132M (+16% QoQ, +24% YoY†)
• Ex-US cosmetic: $250M (+14 QoQ, +18% YoY†)
--
Ex-US total: $382M (35% therapeutic; 65% cosmetic) was 28% of worldwide total.


†Ex-US YoY growth measured in local currency, which eliminates the effect of fluctuating exchange rates.

*In the US market, botulinum-toxin sales for cosmetic indications are seasonally stronger during the second and fourth calendar quarters than the first and third calendar quarters.